SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

SCHEDULE 13G/A

 

 

 

Under the Securities Exchange Act of 1934
 
(Amendment No. 1)*
 
  ANI Pharmaceuticals, Inc.  
(Name of Issuer)
 
  Common Stock, $0.0001 par value  
(Title of Class of Securities)
 
  00182C103  
(CUSIP Number)
 
  September 30, 2024  
(Date of event which requires filing of this statement)
 
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
 
x   Rule 13d-1(b)
¨   Rule 13d-1(c)
¨   Rule 13d-1(d)
 
(Page 1 of 7 Pages)

 

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

 

 

 

 

 

 

CUSIP No. 00182C103

 

 13G/A Page 2 of 7 Pages

 

1

NAMES OF REPORTING PERSONS

Rubric Capital Management LP

 

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

State of Delaware

 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		 5

SOLE VOTING POWER

0

 

6

SHARED VOTING POWER

56,671 shares of Common Stock

 

7

SOLE DISPOSITIVE POWER

0

 

8

SHARED DISPOSITIVE POWER

56,671 shares of Common Stock

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

56,671 shares of Common Stock

 

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.27%

 

12

TYPE OF REPORTING PERSON

PN, IA

 

       

 

 

 

CUSIP No. 00182C103

 

 13G/A Page 3 of 7 Pages

 

1

NAMES OF REPORTING PERSONS

David Rosen

 

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States of America

 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		 5

SOLE VOTING POWER

0

 

6

SHARED VOTING POWER

56,671 shares of Common Stock

 

7

SOLE DISPOSITIVE POWER

0

 

8

SHARED DISPOSITIVE POWER

56,671 shares of Common Stock

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

56,671 shares of Common Stock

 

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.27%

 

12

TYPE OF REPORTING PERSON

IN

 

       

 

 

 

CUSIP No. 00182C103

 

 13G/A Page 4 of 7 Pages

 

Item 1(a). NAME OF ISSUER:
   
  The name of the issuer is ANI Pharmaceuticals, Inc. (the “Issuer”).

 

Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
   
  The Issuer’s principal executive offices are located at 210 Main Street West, Baudette, MN, 56623.

 

Item 2(a). NAME OF PERSON FILING:
   
  This statement is filed by:
   
  (i) Rubric Capital Management LP (“Rubric Capital”), the investment adviser to certain investment funds and/or accounts (collectively, the “Rubric Funds”) that hold the shares of Common Stock (as defined in Item 2(d) below) reported herein; and
     
  (ii) David Rosen (“Mr. Rosen”), Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital.
     
  The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”
   
  The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

 

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
   
  The address of the principal business office of each of the Reporting Persons is 155 East 44th St, Suite 1630, New York, NY 10017.

 

Item 2(c). CITIZENSHIP:
   
  Rubric Capital is a Delaware limited partnership. Mr. Rosen is a citizen of the United States of America.

 

Item 2(d). TITLE OF CLASS OF SECURITIES:
   
  Common Stock, $0.0001 par value (the “Common Stock”).

 

Item 2(e). CUSIP NUMBER:
   
  00182C103

 

 

 

 

CUSIP No. 00182C103

 

 13G/A Page 5 of 7 Pages

 

Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

 

  (a) ¨ Broker or dealer registered under Section 15 of the Act,
       
  (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
       
  (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
       
  (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
       
  (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
       
  (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
       
  (g) x Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
       
  (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
       
  (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
       
  (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
       
  (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

  If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _______________________________________________

 

Item 4. OWNERSHIP.
   
 

The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

 

The percentage set forth in Row (11) of the cover page for each of the Reporting Persons is based on the 21,030,069 shares of Common Stock outstanding as of July 30, 2024, as reported in the Issuer’s Quarterly on Form 10-Q for the quarterly period ended June 30, 2024 filed with the Securities and Exchange Commission on August 6, 2024.

 

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
   
  If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

 

Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
   
  See Item 2.

 

 

 

 

 

CUSIP No. 00182C103

 

 13G/A Page 6 of 7 Pages

 

Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
   
  Not applicable.

 

Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
   
  Not applicable.

 

Item 9. NOTICE OF DISSOLUTION OF GROUP.
   
  Not applicable.

 

Item 10. CERTIFICATION.

 

  Each of the Reporting Persons hereby makes the following certification:
   
  By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

 

 

CUSIP No. 00182C103

 

 13G/A Page 7 of 7 Pages

 

SIGNATURES

 

After reasonable inquiry and to the best of our knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

DATED: November 13, 2024

 

RUBRIC CAPITAL MANAGEMENT LP

 

 

  
By: /s/ Michael Nachmani  
Name: Michael Nachmani  
Title: Chief Operating Officer  

 

 

/s/ David Rosen  
DAVID ROSEN  

 

 

 

 

ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more ANI Pharmaceuticals Charts.
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more ANI Pharmaceuticals Charts.